Convergence Psoriasis Report v1.indd Featuring Phase III PALACE 4: Apremilast Sustains PsA Control after 1-Year Phase 3 Trials Find Guselkumab Significantly Reduces Fatigue with PsA Effects of Ixekizumab on Symptoms of...
Researchers conducted a study to assess the medical and clinical changes patients with rheumatoid...
Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently, or...
Despite numerous effective therapies for patients with psoriatic arthritis (PsA), many do not...
Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A....
The autotaxin inhibitor ziritaxestat proved to be efficacious and tolerable in the first randomised, double-blind, placebo-controlled phase 2 trial ever conducted in patients with diffuse cutaneous systemic sclerosis....
The anti-GM-CSF receptor alpha monoclonal antibody mavrilimumab entailed a lower risk of flare and greater sustained remission compared with placebo in patients with giant cell arteritis. A phase 2, randomised,...
In patients with osteoarthritis, a new study found that the vitamin K antagonist warfarin medication was associated with a significantly increased risk of joint replacement compared with treatment with direct oral...
An Italian cohort study in women observed an increased fracture risk in rheumatoid arthritis and other inflammatory diseases, which was independent of treatment with corticosteroids. “We all know that glucocorticoid-induced...
Reaching RAPID3 and cDAPSA Treatment Targets Linked with Active PsA Control in DMARD-naïve Patients Treated with Apremilast Disease-modifying anti-rheumatic drug (DMARD)-naïve patients achieving Routine Assessment of Patient...
Results from Phase 2 PoS Trial In patients with active psoriatic arthritis (PsA) , deucravacitinib was efficacious versus placebo (PBO) over 16 weeks of treatment. Treatment was well tolerated and the safety profile was...
The orally available, selective tyrosine kinase-2 inhibitor deucravacitinib met the primary and all secondary endpoints and improved quality of life in a randomized, double-blind, placebo-controlled phase 2 trial that included...
